AR035581A1 - Anticuerpos para il-1beta humana - Google Patents

Anticuerpos para il-1beta humana

Info

Publication number
AR035581A1
AR035581A1 ARP010103946A ARP010103946A AR035581A1 AR 035581 A1 AR035581 A1 AR 035581A1 AR P010103946 A ARP010103946 A AR P010103946A AR P010103946 A ARP010103946 A AR P010103946A AR 035581 A1 AR035581 A1 AR 035581A1
Authority
AR
Argentina
Prior art keywords
1beta
tyr
gly
asp
amino acid
Prior art date
Application number
ARP010103946A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR035581(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR035581A1 publication Critical patent/AR035581A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
ARP010103946A 2000-08-22 2001-08-17 Anticuerpos para il-1beta humana AR035581A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0020685.4A GB0020685D0 (en) 2000-08-22 2000-08-22 Organic compounds

Publications (1)

Publication Number Publication Date
AR035581A1 true AR035581A1 (es) 2004-06-16

Family

ID=9898090

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103946A AR035581A1 (es) 2000-08-22 2001-08-17 Anticuerpos para il-1beta humana

Country Status (36)

Country Link
US (3) US7446175B2 (instruction)
EP (1) EP1313769B2 (instruction)
JP (2) JP4271936B2 (instruction)
KR (2) KR100910789B1 (instruction)
CN (1) CN100547003C (instruction)
AR (1) AR035581A1 (instruction)
AT (1) ATE396206T1 (instruction)
AU (2) AU2001295490B2 (instruction)
BE (1) BE2009C057I2 (instruction)
BR (1) BR0113420A (instruction)
CA (1) CA2420231C (instruction)
CY (2) CY1108779T1 (instruction)
CZ (1) CZ304470B6 (instruction)
DE (2) DE60134148D1 (instruction)
DK (1) DK1313769T4 (instruction)
EC (1) ECSP034490A (instruction)
ES (1) ES2305110T5 (instruction)
FR (1) FR09C0062I2 (instruction)
GB (1) GB0020685D0 (instruction)
HU (2) HU228159B1 (instruction)
IL (2) IL154465A0 (instruction)
LU (1) LU91624I2 (instruction)
MX (1) MXPA03001590A (instruction)
MY (1) MY130248A (instruction)
NL (1) NL300427I1 (instruction)
NO (3) NO332609B1 (instruction)
NZ (2) NZ534269A (instruction)
PE (1) PE20020319A1 (instruction)
PL (1) PL212480B1 (instruction)
PT (1) PT1313769E (instruction)
RU (1) RU2286351C2 (instruction)
SI (1) SI1313769T2 (instruction)
SK (1) SK288089B6 (instruction)
TW (1) TWI321568B (instruction)
WO (1) WO2002016436A2 (instruction)
ZA (1) ZA200301275B (instruction)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339426A4 (en) * 2000-11-08 2004-06-30 Human Genome Sciences Inc ANTIBODIES WITH IMMUNOSPECIFIC BINDING TO TRAIL RECEPTORS
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
RS52889B (sr) 2002-09-06 2014-02-28 Amgen Inc Terapijsko humano anti-il-1r1 monoklonsko antitelo
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
ES2567198T3 (es) * 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP4989456B2 (ja) * 2004-02-26 2012-08-01 ベイラー リサーチ インスティテュート 関節炎の全身処置のための組成物および方法
AU2012213934B9 (en) * 2005-01-26 2013-07-25 Amgen Fremont Inc. Antibodies against interleukin-1 beta
CA2590164A1 (en) * 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
GB0509512D0 (en) * 2005-05-10 2005-06-15 Novartis Ag Organic compounds
CA2612760C (en) * 2005-06-21 2015-05-12 Xoma Technology Ltd. Il-1.beta. binding antibodies and fragments thereof
US20100015146A1 (en) * 2005-10-14 2010-01-21 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
WO2007050607A2 (en) * 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
CA2648223A1 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
EP2094306A2 (en) 2006-12-20 2009-09-02 XOMA Technology Ltd. Treatment of il-1-beta related diseases
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
CN101678104A (zh) 2007-05-29 2010-03-24 诺瓦提斯公司 抗IL-1β治疗的新适应症
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
PL2391650T3 (pl) * 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
EP2899209A1 (en) 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY31861A (es) * 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
CA2727171A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
CA2729949A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8545846B2 (en) * 2008-09-05 2013-10-01 Xoma Technology, Ltd. Methods for treating IL-1β related diseases by administering an anti-IL-1β antibody
US20100150864A1 (en) * 2008-10-20 2010-06-17 Abbott Laboratories, Inc. Antibodies that bind to il-18 and methods of purifying the same
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
EP2427209A1 (en) * 2009-05-06 2012-03-14 Novartis AG Anti-il1- antibody combination therapy
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
CN102612524A (zh) * 2009-09-01 2012-07-25 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2010311567B2 (en) 2009-10-26 2015-03-26 Chugai Seiyaku Kabushiki Kaisha Method for the production of a glycosylated immunoglobulin
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201201526A1 (ru) 2010-05-07 2013-06-28 Ксома Текнолоджи Лтд. Способы лечения состояний, связанных с il-1b
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2013002270A (es) 2010-08-26 2013-05-14 Abbvie Inc Inmonoglubinas de dominio variable doble y usos de las mismas.
AU2012242666A1 (en) 2011-04-15 2013-11-28 Merck Patent Gmbh Anti- IL-1R1 inhibitors for use in cancer
EP2731971A1 (en) 2011-07-12 2014-05-21 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
BR112014007253A2 (pt) * 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
JP6342812B2 (ja) 2011-12-14 2018-06-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
WO2013087911A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
US10167335B2 (en) * 2012-02-13 2019-01-01 Agency For Science, Technology And Research IL-1β neutralizing human monoclonal antibodies
CN103588878A (zh) * 2012-08-15 2014-02-19 江苏泰康生物医药有限公司 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
CN104884472B (zh) 2012-11-01 2021-10-15 艾伯维公司 抗-vegf/dll4双重可变结构域免疫球蛋白及其用途
EP3750917A1 (en) 2012-11-05 2020-12-16 Delenex Therapeutics AG Binding members to il-1 beta
EP2919811B1 (en) 2012-11-16 2018-12-26 Novartis AG Use of il-1beta binding antibodies for treating peripheral arterial disease
EP4001307A1 (en) 2012-12-17 2022-05-25 Cell Medica Inc. Antibodies against il-1 beta
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
WO2015083120A1 (en) 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2016008851A1 (en) * 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anti-il-1b antibodies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
CA2963606A1 (en) 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AU2016272900A1 (en) 2015-06-04 2017-12-07 Novartis Ag Use of IL-1 beta binding antibodies to treat peripheral arterial disease
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3426775A1 (en) 2016-03-10 2019-01-16 Novartis AG Chemically modified messenger rna's
JP2019521161A (ja) 2016-07-21 2019-07-25 ノバルティス アーゲー 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用
CA3045296A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554343A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology HEALTHY AND SICK BARRIER TISSUE CELL ATLAS
US20200239564A1 (en) 2017-08-25 2020-07-30 Novartis Ag Use of canakinumab
JP2020533353A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー アルコール性肝炎の治療のためのｉｌ−１ｂ結合抗体の使用
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
MX2020011909A (es) * 2018-05-09 2021-01-29 Novartis Ag Uso de canakinumab.
SG11202010579XA (en) 2018-06-01 2020-12-30 Novartis Ag Binding molecules against bcma and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB2575853A (en) * 2018-07-25 2020-01-29 Robert Wotherspoon Hugh IL-1ß binding antibody
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
WO2020093957A1 (zh) 2018-11-07 2020-05-14 泽达生物医药有限公司 结合人IL-1β的抗体、其制备方法和用途
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3897637A1 (en) 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
GB201901187D0 (en) 2019-01-29 2019-03-20 Autolus Ltd Treatment of neurotoxicity and/or cytokine release syndrome
EA202192029A1 (ru) 2019-02-15 2021-10-27 Новартис Аг Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220356240A1 (en) * 2019-09-26 2022-11-10 Beth Israel Deaconess Medical Center, Inc. Anti-inflammatory therapy in arrhythmogenic cardiomyopathy (acm)
EP4073115A1 (en) 2019-12-09 2022-10-19 Novartis AG Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IL293889A (en) 2019-12-20 2022-08-01 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
CN115551538A (zh) * 2020-01-21 2022-12-30 拓维创新生物科技(香港)有限公司 干扰IL-1β受体信号转导的药剂
CN115836089A (zh) 2020-05-13 2023-03-21 迪斯克医药公司 用于治疗骨髓纤维化的抗血幼素（hjv）抗体
US20230220065A1 (en) * 2020-06-16 2023-07-13 Academia Sinica Antibodies to interleukin-1beta and uses thereof
AU2021297099A1 (en) 2020-06-23 2023-01-05 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
MX2023005353A (es) 2020-11-06 2023-05-22 Novartis Ag Moleculas de union a cd19 y usos de las mismas.
WO2022167916A1 (en) 2021-02-03 2022-08-11 Novartis Ag Use of il-1b binding antibodies for treating neuroinflammatory disorders
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
JP2024519893A (ja) 2021-05-24 2024-05-21 ノバルティス アーゲー 変形性関節症の治療方法
US20240294626A1 (en) 2021-06-22 2024-09-05 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa
WO2025068957A1 (en) 2023-09-29 2025-04-03 Novartis Ag Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
GB202400340D0 (en) 2024-01-10 2024-02-21 Wotherspoon Hugh Robert IL-1B binding antibody

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534858A (en) * 1895-02-26 Workman s time-recorder
CA1172789A (en) 1980-09-25 1984-08-14 Hideo Kasahara POLYMERIC MATERIAL COMPRISING A POLYAMIDE BONDED TO A COPOLYMER CONTAINING AN IMIDE OF AN .alpha.,.beta. UNSATURATED CARBOXYLIC ACID
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
DE68925935T2 (de) 1988-10-01 1996-08-14 Otsuka Pharma Co Ltd Antikörper gegen Interleukin-1-beta
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3714683B2 (ja) 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BE2009C057I2 (instruction) 2021-01-28
CZ2003505A3 (cs) 2003-05-14
EP1313769A2 (en) 2003-05-28
US7993878B2 (en) 2011-08-09
IL154465A0 (en) 2003-09-17
SK288089B6 (sk) 2013-06-03
AU9549001A (en) 2002-03-04
US7446175B2 (en) 2008-11-04
CY2009019I1 (el) 2012-01-25
PL360358A1 (en) 2004-09-06
US8273350B2 (en) 2012-09-25
PL212480B1 (pl) 2012-10-31
BR0113420A (pt) 2003-07-29
BRPI0113420B1 (pt) 2002-02-28
BRPI0113420B8 (instruction) 2021-05-25
HU228159B1 (en) 2013-01-28
PE20020319A1 (es) 2002-06-11
NO20030827D0 (no) 2003-02-21
SK2132003A3 (en) 2003-10-07
AU2001295490B2 (en) 2005-06-16
IL154465A (en) 2010-11-30
DK1313769T4 (da) 2011-12-05
CA2420231C (en) 2011-04-26
TWI321568B (en) 2010-03-11
NZ534269A (en) 2006-04-28
HUP0300806A3 (en) 2005-09-28
CZ304470B6 (cs) 2014-05-21
KR100910789B1 (ko) 2009-08-04
KR20080056316A (ko) 2008-06-20
CN1484652A (zh) 2004-03-24
ES2305110T3 (es) 2008-11-01
EP1313769B2 (en) 2011-11-09
HK1061403A1 (en) 2004-09-17
HUP0300806A2 (hu) 2003-12-29
SI1313769T2 (sl) 2012-01-31
LU91624I9 (instruction) 2018-11-19
DE122009000078I1 (de) 2010-03-25
FR09C0062I1 (instruction) 2010-08-01
CN100547003C (zh) 2009-10-07
WO2002016436A3 (en) 2002-06-20
ATE396206T1 (de) 2008-06-15
MY130248A (en) 2007-06-29
NL300427I2 (en) 2010-02-01
NO2012018I2 (no) 2012-11-21
US20090081732A1 (en) 2009-03-26
DK1313769T3 (da) 2008-09-15
HUS1300015I1 (hu) 2021-05-28
NO332609B1 (no) 2012-11-19
JP4271936B2 (ja) 2009-06-03
CY2009019I2 (el) 2017-07-12
FR09C0062I2 (fr) 2010-12-31
NO2017052I2 (no) 2018-05-14
JP2004506448A (ja) 2004-03-04
CA2420231A1 (en) 2002-02-28
ECSP034490A (es) 2003-03-31
KR20030034140A (ko) 2003-05-01
JP2008295456A (ja) 2008-12-11
US20110256151A1 (en) 2011-10-20
ZA200301275B (en) 2004-04-02
NO20030827L (no) 2003-04-14
LU91624I2 (fr) 2010-01-25
PT1313769E (pt) 2008-08-26
SI1313769T1 (sl) 2008-10-31
GB0020685D0 (en) 2000-10-11
ES2305110T5 (es) 2012-03-13
MXPA03001590A (es) 2003-06-04
EP1313769B1 (en) 2008-05-21
CY1108779T1 (el) 2012-01-25
WO2002016436A2 (en) 2002-02-28
NZ524199A (en) 2004-09-24
NO2012018I1 (no) 2012-12-10
US20040063913A1 (en) 2004-04-01
DE60134148D1 (de) 2008-07-03
NL300427I1 (en) 2010-02-01
RU2286351C2 (ru) 2006-10-27
NO2017052I1 (no) 2017-10-11

Similar Documents

Publication Publication Date Title
AR035581A1 (es) Anticuerpos para il-1beta humana
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
PE20011219A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
HRP20181069T1 (hr) Antagonistička protutijela na il-17
PE20030104A1 (es) Anticuerpos humanos para cd154
BR0207151A (pt) Moléculas de aglutinação terapêuticas
CY1124289T1 (el) Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
ECSP066432A (es) Moléculas de enlace terapéuticas
AR046379A1 (es) Una molecula de enlace de mcp-1 humana, un proceso para dicha produccion, construcciones de adn, un vector de expresion, composiciones farmaceuticas y el uso de dicha molecula de enlace de mcp-1 para la preparacion de un medicamento
CL2010000790A1 (es) Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03).
NO20061070L (no) Antistoffer mot parathyoidhormon (PTH) og anvendelser derav
EP2796466A3 (en) Humanized antibody molecules specific for IL-31
RS54271B1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
RS51468B (en) COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137)
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
PE20050925A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
RS51829B (sr) Ljudska antitela specifična za interleukin 15 (il-15)
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
PE20110797A1 (es) Anticuerpos anti mn
UY29573A1 (es) Anticuerpos dirigidos contra cd20 y sus usos
RS51908B (en) Antibodies against clostridium difficile toxins and uses thereof
RS52860B (en) ANTI-ILT7 ANTITELO

Legal Events

Date Code Title Description
FG Grant, registration